19,200 Shares in Parabilis Medicines, Inc. $PBLS Acquired by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Parabilis Medicines, Inc. (NASDAQ:PBLS) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 19,200 shares of the company’s stock, valued at approximately $526,000.

Separately, Persistent Asset Partners Ltd bought a new position in shares of Parabilis Medicines in the second quarter worth $113,000.

Parabilis Medicines Stock Performance

NASDAQ PBLS opened at $39.36 on Friday. The stock has a 50 day simple moving average of $31.59. Parabilis Medicines, Inc. has a 12 month low of $24.51 and a 12 month high of $41.49.

Parabilis Medicines (NASDAQ:PBLS) last released its earnings results on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The company had revenue of $0.15 million for the quarter. On average, research analysts expect that Parabilis Medicines, Inc. will post -2.05 EPS for the current fiscal year.

Insider Buying and Selling at Parabilis Medicines

In related news, major shareholder Guy Levy acquired 500,000 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $20.00 per share, for a total transaction of $10,000,000.00. Following the transaction, the insider owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. The trade was a 94.88% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alan Sebulsky acquired 12,500 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $20.00 per share, with a total value of $250,000.00. Following the transaction, the director directly owned 12,500 shares in the company, valued at approximately $250,000. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 530,000 shares of company stock worth $10,723,528 in the last ninety days.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PBLS shares. Leerink Partners started coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They set an “outperform” rating and a $40.00 price objective on the stock. Evercore started coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They issued an “outperform” rating for the company. Bank of America initiated coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They set a “buy” rating and a $45.00 target price on the stock. Lifesci Capital upgraded shares of Parabilis Medicines to a “strong-buy” rating in a research report on Monday, July 6th. Finally, Wall Street Zen upgraded shares of Parabilis Medicines to a “hold” rating in a research report on Saturday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $41.67.

Parabilis Medicines Profile

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.